Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care Relationship and Stock Price Updates - Research Report on

    Marketing Rights Acquisitions, PDUFA Date Extensions, Accountable Care
Relationship and Stock Price Updates - Research Report on Forest Laboratories,
              Biogen, Bristol-Myers, Express Scripts, and Aetna

PR Newswire

NEW YORK, December 5, 2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Forest
Laboratories, Inc. (NYSE: FRX), Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers
Squibb Co. (NYSE: BMY), Express Scripts Holding Company (NASDAQ: ESRX), and
Aetna Inc. (NYSE: AET). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Forest Laboratories, Inc. Research Report   

On December 2, 2013, Forest Laboratories, Inc. (Forest Laboratories) reported
that its wholly owned subsidiary, Forest Laboratories Holding Limited (FLHL)
is acquiring exclusive rights in the United States for Saphris (asenapine)
sublingual tablets, a treatment for adult patients with schizophrenia or acute
bipolar mania, from Merck Sharp & Dohme B.V. (Merck Sharp), a wholly owned
subsidiary of Merck & Co., Inc. Forest Laboratories informed that under the
terms of the agreement FLHL will make an upfront payment of $240 million and
additional payments to Merck Sharp based on defined sales milestones. The
Company also reported that Merck Sharp will remain responsible for product
supply, and FLHL will take over the responsibility for continued
commercialization, including completing certain post marketing studies of
Saphris, following a transition period, and will be the marketing
authorization holder. The Company expects the agreement to close in early 2014
pending regulatory review and satisfaction of all closing conditions. The Full
Research Report on Forest Laboratories, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/ea24_FRX

Biogen Idec Inc. Research Report

On December 2, 2013, Biogen Idec Inc. (Biogen Idec) announced that the US Food
and Drug Administration (FDA) has extended the initial Prescription Drug User
Free Act (PDUFA) date for its review of the Biologics License Application
(BLA) for ALPROLIX, the Company's investigational long-lasting recombinant
factor IX Fc fusion protein candidate for hemophilia B. Biogen Idec informed
that the PDUFA date was extended by three months, which is the standard
extension period. Biogen Idec added that in response to a request from the
FDA, it has submitted additional information related to the validation of a
manufacturing step for ALPROLIX. The Full Research Report on Biogen Idec Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b95b_BIIB

Bristol-Myers Squibb Co. Research Report

On December 2, 2013, Bristol-Myers Squibb Co.'s (Bristol-Myers) stock rose
0.19%, ending the day's session at $51.48. Over the previous three trading
sessions, shares of Bristol-Myers declined 0.77%, compared to the S&P 500
Index, which declined 0.10% during the same period. The Full Research Report
on Bristol-Myers Squibb Co. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

Express Scripts Holding Company Research Report

On December 2, 2013, Express Scripts Holding Company (Express Scripts)
declined 0.48%, ending the day's session at $67.03. Over the previous three
trading sessions, shares of Express Scripts declined 0.34%, compared to the
Nasdaq Composite Index, which gained 0.68% during the same period. The Full
Research Report on Express Scripts Holding Company - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/91a7_ESRX

Aetna Inc. Research Report 

On December 2, 2013, Aetna Inc. (Aetna) and PinnacleHealth System jointly
announced a new accountable care agreement, designed to improve the quality of
care and lower overall health care costs for Aetna commercial plan members in
the Harrisburg, Pennsylvania, area. According to Aetna, the collaboration will
use PinnacleHealth's comprehensive, integrated system of physicians,
hospitals, and ambulatory services to give area employers better health care
options for their employees by - creating a more coordinated patient
experience, saving employees money when they use providers aligned with
PinnacleHealth, and improving health care outcomes. Aetna added that it will
introduce both fully insured and self-insured health plans in Central
Pennsylvania that will use PinnacleHealth's community-based systems of care
and its network of highly respected physicians. Aetna expects the first
product, for groups of more than 51 employees, to be available on April 1,
2014, and a small-group product for groups of between two and 50 employees to
be introduced on July 1, 2014. The Full Research Report on Aetna Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cbe9_AET

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.